|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MLLT10 |
 Gene summary |
| Basic gene Info. | Gene symbol | MLLT10 |
| Gene name | myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 | |
| Synonyms | AF10 | |
| Cytomap | UCSC genome browser: 10p12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001195626.1, NM_001195627.1,NM_001195628.1,NM_001195630.1,NM_004641.3, NM_001009569.1, | |
| Description | ALL1-fused gene from chromosome 10 proteinprotein AF-10type I AF10 proteintype III AF10 proteintype IV AF10 protein | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602409 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000078403 | ||
| HPRD : 03874 | ||
| Vega : OTTHUMG00000017799 | ||
| Protein | UniProt: P55197 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MLLT10 | |
| BioGPS: 8028 | ||
| Pathway | NCI Pathway Interaction Database: MLLT10 | |
| KEGG: MLLT10 | ||
| REACTOME: MLLT10 | ||
| Pathway Commons: MLLT10 | ||
| Context | iHOP: MLLT10 | |
| ligand binding site mutation search in PubMed: MLLT10 | ||
| UCL Cancer Institute: MLLT10 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 17868029 |
| Top |
| Ligand binding site mutations for MLLT10 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C47 | S48R | HNSC | 1 | E179 | E180K | SKCM | 1 | C162 | Q164H | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MLLT10 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | E179 | E180K | -1.292656 | C162 | Q164H | -0.36072907 | C47 | S48R | -0.33802899 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MLLT10 from PDB |
| Top |
| Differential gene expression and gene-gene network for MLLT10 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MLLT10 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0023467 | Leukemia, Myeloid, Acute | 20 | Biomarker |
| umls:C0025286 | Meningioma | 1 | Biomarker, GeneticVariation |
| umls:C0007134 | Carcinoma, Renal Cell | 1 | Biomarker |
| umls:C0025202 | Melanoma | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MLLT10 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MLLT10 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 5dag | A | C162 | ZN | ZINC(2+) | 5dah | A | C162 | ZN | ZINC(2+) | 5dah | B | C162 | ZN | ZINC(2+) | 5dag | A | C47 | ZN | ZINC(2+) | 5dah | A | C47 | ZN | ZINC(2+) | 5dah | B | C47 | III | Peptide ligand (LEU,ALA,THR,LYS,ALA,ALA,ARG,LYS,SER) | 5dah | A | E179 | III | Peptide ligand (LEU,ALA,THR,LYS,ALA,ALA,ARG,LYS,SER) | 5dah | B | E179 |
| Top |
| Conservation information for LBS of MLLT10 |
| Multiple alignments for P55197 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |